CRDF Q2 2020 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43,000-68.8% YoY

Gross Profit

$43,000100.0% margin

Operating Income

-$4M-9539.5% margin

Net Income

-$4M-9590.7% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-36.8%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$30M

Total Liabilities

$6M

Stockholders' Equity

$24M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43,000	$138,000	-68.8%
Gross Profit	$43,000	-$3M	+101.6%
Operating Income	-$4M	-$4M	+2.8%
Net Income	-$4M	-$4M	+0.0%